Fulminant type 1 diabetes mellitus: A new class of type 1 diabetes

Advances in Experimental Medicine and Biology

Volumn 771, Issue , 2013, Pages 20-23

  Shibasaki, Saeko ^a   Imagawa, Akihisa ^b   Hanafusa, Toshiaki ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INSULIN; PIG INSULIN; ANTIDIABETIC AGENT;

ARTICLE; BLOOD GLUCOSE MONITORING; CONTINUOUS INFUSION; DIABETIC ANGIOPATHY; DIABETIC KETOACIDOSIS; DIABETOGENESIS; DISEASE CLASSIFICATION; FLU LIKE SYNDROME; FULMINANT INSULIN DEPENDENT DIABETES MELLITUS; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; JAPAN; NONHUMAN; ONSET AGE; PANCREAS ISLET BETA CELL; PANCREAS ISLET DISEASE; PREVALENCE; VIRUS INFECTION; ACUTE DISEASE; CLASSIFICATION; DIABETES MELLITUS; REVIEW; SEVERITY OF ILLNESS INDEX;

ACUTE DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; JAPAN; PREVALENCE; SEVERITY OF ILLNESS INDEX;

MLCS; MLOWN;

EID: 84874529931     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5441-0_3     Document Type: Article

References (16)

1. lmagawa A, Hanafusa T, Miyagawa J et al. A novel subtype of type I diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 2000; 342:301-307.
2. Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab 2007; 3:36-45.
3. lmagawa A, Hanafusa T, Uchigata Y et al. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 2003; 26:2345-2352.
4. Imagawa A, Hanafusa T, Uchigata Y et al. Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. Diabetologia 2005; 48:294-300.
5. Kawasaki E, Imagawa A, Makino H et al. Differences in the contribution of CTLA4 gene to susceptibility to fulm inant and type IA diabetes in Japanese patients. Diabetes Care 2008; 31:1608-1610.
6. Kawabata Y, Ikegami H, Awata T et al. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia 2009; 52:2513-2521.
7. Hanafusa T, Imagawa A, Iwahashi H et al. Report of the Japan Diabetes Society's committee on research on fulminant type 1 diabetes mellitu s: Analysis of antiviral antibodies at disease onset. J Japan Diab Soc 2008; 51:531-536.
8. Shibasaki S, Imagawa A, Tauriainen S et al. Expression of Toll-like receptors in the pancreas of recent-onset fulminant type 1 diabetes. Endocrine J 2010; 57:211-219.
9. Aida K, Nishida Y, Tanaka S et al. RIG- and MDA5-initiated innate immuni ty linked with adaptive immunity accelerates β-cell death in fulminant type 1 diabetes. Diabetes 2011; 60:884-889.
10. Kotani R, Nagata M, Imagawa A et al. T-lymphocyte response against pancreatic beta cell antigens in fulminant Type 1 diabetes Diabetologia 2004; 47:1285-1291.
11. Tanaka S, Nishida Y, Aida K et al. Enterovirus infection, CXC chemokine ligand 10 (CXCL10) and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes. Diabetes 2009; 58:2285-2291.
12. Endo T, Takizawa S, Tanaka S et al. Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes. Diabetes 2009; 58:732-737.
13. Takizawa S, Endo T, Wanjia X et al. HSP 10 is a new autoantigen in both autoimmune pancreatitis and fulminant type 1 diabetes. Biochem Biophys Res Commun 2009; 386:192-196.
14. Shibasaki S, Imagawa A, Terasaki J et al. Endoge nous insulin secretion even at a very low level contributes to the stability of blood glucose control in fulminant type 1 diabetes. J Diab Invest 2010; 1:283-285.
15. Murase Y, Imagawa A, Hanafusa T, et al. Fulminant type 1 diabetes as a high risk group for diabetic microangiopathy-a nationwide 5-year-study in Japan. Diabetologia 2007; 50:531-537.
16. Sano H, Terasaki J, Mishiba Y et al. Exenatide, glucagon-like peptide-1 receptor agonist suppresses pancreatic β-cell destruction induced by encephalomyocarditis virus. Biochem Biophys Res Commun 2011; 404:756-761.